Literature DB >> 23271326

Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer.

Xiaohong R Yang1, Jonine D Figueroa, Stephen M Hewitt, Roni T Falk, Ruth M Pfeiffer, Jolanta Lissowska, Beata Peplonska, Louise A Brinton, Montserrat Garcia-Closas, Mark E Sherman.   

Abstract

Molecular and morphological alterations related to carcinogenesis have been found in terminal duct lobular units (TDLUs), the microscopic structures from which most breast cancer precursors and cancers develop, and therefore, analysis of these structures may reveal early changes in breast carcinogenesis and etiologic heterogeneity. Accordingly, we evaluated relationships of breast cancer risk factors and tumor pathology to estrogen receptor (ER) and progesterone receptor (PR) expression in TDLUs surrounding breast cancers. We analyzed 270 breast cancer cases included in a population-based breast cancer case-control study conducted in Poland. TDLUs were mapped in relation to breast cancer: within the same block as the tumor (TDLU-T), proximal to tumor (TDLU-PT), or distant from (TDLU-DT). ER/PR was quantitated using image analysis of immunohistochemically stained TDLUs prepared as tissue microarrays. In surgical specimens containing ER-positive breast cancers, ER and PR levels were significantly higher in breast cancer cells than in normal TDLUs, and higher in TDLU-T than in TDLU-DT or TDLU-PT, which showed similar results. Analyses combining DT-/PT TDLUs within subjects demonstrated that ER levels were significantly lower in premenopausal women versus postmenopausal women (odds ratio [OR] = 0.38, 95 % confidence interval [CI] = 0.19, 0.76, P = 0.0064) and among recent or current menopausal hormone therapy users compared with never users (OR = 0.14, 95 % CI = 0.046-0.43, P (trend) = 0.0006). Compared with premenopausal women, TDLUs of postmenopausal women showed lower levels of PR (OR = 0.90, 95 % CI = 0.83-0.97, P (trend) = 0.007). ER and PR expression in TDLUs was associated with epidermal growth factor receptor (EGFR) expression in invasive tumors (P = 0.019 for ER and P = 0.03 for PR), but not with other tumor features. Our data suggest that TDLUs near breast cancers reflect field effects, whereas those at a distance demonstrate influences of breast cancer risk factors on at-risk breast tissue. Analyses of mapped TDLUs may provide information about the sequence of molecular changes occurring in breast carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271326      PMCID: PMC4154606          DOI: 10.1007/s10549-012-2380-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  34 in total

1.  Regulation by estrogen through the 5'-flanking region of the transforming growth factor alpha gene.

Authors:  T Saeki; A Cristiano; M J Lynch; M Brattain; N Kim; N Normanno; N Kenney; F Ciardiello; D S Salomon
Journal:  Mol Endocrinol       Date:  1991-12

2.  The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol.

Authors:  S A Khan; A Sachdeva; S Naim; M M Meguid; W Marx; H Simon; J D Halverson; P J Numann
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-10       Impact factor: 4.254

3.  Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle.

Authors:  G Söderqvist; B von Schoultz; E Tani; L Skoog
Journal:  Am J Obstet Gynecol       Date:  1993-03       Impact factor: 8.661

4.  Relationship of estrogen and progesterone receptor protein levels in carcinomatous and adjacent non-neoplastic epithelium of the breast: a histopathologic and image cytometric study.

Authors:  F B Smith; C D Puerto; P Sagerman
Journal:  Breast Cancer Res Treat       Date:  2001-02       Impact factor: 4.872

5.  Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen.

Authors:  K B Horwitz; Y Koseki; W L McGuire
Journal:  Endocrinology       Date:  1978-11       Impact factor: 4.736

6.  Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle.

Authors:  C Markopoulos; U Berger; P Wilson; J C Gazet; R C Coombes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-14

7.  Estrogen receptor expression of benign breast epithelium and its association with breast cancer.

Authors:  S A Khan; M A Rogers; J A Obando; A Tamsen
Journal:  Cancer Res       Date:  1994-02-15       Impact factor: 12.701

8.  Analysis of terminal duct lobular unit involution in luminal A and basal breast cancers.

Authors:  Xiaohong R Yang; Jonine D Figueroa; Roni T Falk; Hong Zhang; Ruth M Pfeiffer; Stephen M Hewitt; Jolanta Lissowska; Beata Peplonska; Louise Brinton; Montserrat Garcia-Closas; Mark E Sherman
Journal:  Breast Cancer Res       Date:  2012-04-18       Impact factor: 6.466

9.  Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast.

Authors:  S Battersby; B J Robertson; T J Anderson; R J King; K McPherson
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

10.  Repeated observation of breast tumor subtypes in independent gene expression data sets.

Authors:  Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 12.779

View more
  10 in total

1.  Tumor intrinsic subtype is reflected in cancer-adjacent tissue.

Authors:  Patricia Casbas-Hernandez; Xuezheng Sun; Erick Roman-Perez; Monica D'Arcy; Rupninder Sandhu; Asahi Hishida; Kirk K McNaughton; Xiaohong R Yang; Liza Makowski; Mark E Sherman; Jonine D Figueroa; Melissa A Troester
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12-02       Impact factor: 4.254

2.  A human breast atlas integrating single-cell proteomics and transcriptomics.

Authors:  G Kenneth Gray; Carman Man-Chung Li; Jennifer M Rosenbluth; Laura M Selfors; Nomeda Girnius; Jia-Ren Lin; Ron C J Schackmann; Walter L Goh; Kaitlin Moore; Hana K Shapiro; Shaolin Mei; Kurt D'Andrea; Katherine L Nathanson; Peter K Sorger; Sandro Santagata; Aviv Regev; Judy E Garber; Deborah A Dillon; Joan S Brugge
Journal:  Dev Cell       Date:  2022-05-25       Impact factor: 13.417

3.  In search of novel drug target sites on estrogen receptors using RNA aptamers.

Authors:  Daiying Xu; Vamsee-Krishna Chatakonda; Antonis Kourtidis; Douglas S Conklin; Hua Shi
Journal:  Nucleic Acid Ther       Date:  2014-03-03       Impact factor: 5.486

4.  In vivo type 2 cannabinoid receptor-targeted tumor optical imaging using a near infrared fluorescent probe.

Authors:  Shaojuan Zhang; Pin Shao; Mingfeng Bai
Journal:  Bioconjug Chem       Date:  2013-10-29       Impact factor: 4.774

5.  Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease.

Authors:  Heidi N Hilton; Tram B Doan; J Dinny Graham; Samantha R Oakes; Audrey Silvestri; Nicole Santucci; Silke Kantimm; Lily I Huschtscha; Christopher J Ormandy; John W Funder; Evan R Simpson; Elizabeth S Kuczek; Peter J Leedman; Wayne D Tilley; Peter J Fuller; George E O Muscat; Christine L Clarke
Journal:  Oncotarget       Date:  2014-09-30

6.  Evaluation of Antioxidant Intakes in Relation to Inflammatory Markers Expression Within the Normal Breast Tissue of Breast Cancer Patients.

Authors:  Danielle Larouche; Mirette Hanna; Sue-Ling Chang; Simon Jacob; Bernard Têtu; Caroline Diorio
Journal:  Integr Cancer Ther       Date:  2016-11-30       Impact factor: 3.279

7.  Association between local inflammation and breast tissue age-related lobular involution among premenopausal and postmenopausal breast cancer patients.

Authors:  Mirette Hanna; Isabelle Dumas; Michèle Orain; Simon Jacob; Bernard Têtu; François Sanschagrin; Alexandre Bureau; Brigitte Poirier; Caroline Diorio
Journal:  PLoS One       Date:  2017-08-28       Impact factor: 3.240

8.  RSK2 Maintains Adult Estrogen Homeostasis by Inhibiting ERK1/2-Mediated Degradation of Estrogen Receptor Alpha.

Authors:  Katarzyna A Ludwik; Zachary M Sandusky; Kimberly M Stauffer; Yu Li; Kelli L Boyd; George A O'Doherty; Thomas P Stricker; Deborah A Lannigan
Journal:  Cell Rep       Date:  2020-07-21       Impact factor: 9.423

9.  Association of reproductive history with breast tissue characteristics and receptor status in the normal breast.

Authors:  Marike Gabrielson; Flaminia Chiesa; Catharina Behmer; Katarina Rönnow; Kamila Czene; Per Hall
Journal:  Breast Cancer Res Treat       Date:  2018-03-30       Impact factor: 4.872

10.  Association between low estrogen receptor positive breast cancer and staining performance.

Authors:  Dennis Caruana; Wei Wei; Sandra Martinez-Morilla; David L Rimm; Emily S Reisenbichler
Journal:  NPJ Breast Cancer       Date:  2020-02-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.